Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension*

Pepke‐Zaba, Joanna; Gilbert, Clare; Collings, Lorraine; Brown, Martin C.

doi:10.1378/chest.07-0592

Cited by 87 publications

(75 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Summary scores are scaled to a mean of 50 and standard deviation of 10 in the general U.S. population. The SF-36 has been validated and demonstrated responsiveness to change in a variety of patient groups; it is commonly used in PAH clinical trials (30,31).…”

Section: Methodsmentioning

confidence: 99%

Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension

et al. 2016

View full text Add to dashboard Cite

Rationale: Pulmonary arterial hypertension is a progressive disease with high morbidity and mortality despite advances in medical therapy. The relationship between patient-related outcomes, such as healthrelated quality of life (HRQOL), and survival is not well described.Objective: To assess the relationship between HRQOL and outcomes in patients with pulmonary arterial hypertension.Methods: Consecutive patients with right heart catheterization-proven pulmonary arterial hypertension who completed the Medical Outcomes Survey Short Form-36 survey (SF-36) were included. Demographic, clinical, physiological, and hemodynamic data were collected at baseline. Survival was assessed from the time of diagnosis of pulmonary arterial hypertension. Cox proportional hazard models were constructed to assess the relationship between HRQOL and transplant-free survival.Measurements and Main Results: Eighty-seven patients with pulmonary arterial hypertension were enrolled and followed prospectively for a median of 3.8 years. At baseline, HRQOL was significantly worse than U.S. normal values for six of eight domains of the SF-36. Several domains demonstrated moderate correlation (r value > 0.40) with 6-minute-walk distance and World Health Organization functional class; there were no significant associations with hemodynamics. In univariable Cox proportional hazard models, six of eight domains and both summary scores were significantly associated with survival. In multivariable models, adjusted for age, disease type, and cardiac function, these relationships largely persisted. Conclusions:In this cohort of patients with pulmonary arterial hypertension, HRQOL, as assessed by the SF-36, was strongly associated with transplant-free survival. These relationships persisted when controlling for potential confounders such as disease type and disease severity. These findings suggest that HRQOL may be an important predictor of outcomes in pulmonary arterial hypertension and therefore a target for future therapeutic interventions.

show abstract

Section: Methodsmentioning

confidence: 99%

Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension

et al. 2016

View full text Add to dashboard Cite

show abstract

“…This is particularly important when compared with incremental improvements in QOL that medical therapies provide patients with advanced lung disease. [34][35][36] Yet, the physical gains of transplant must be balanced against the impaired psychologic well-being that remained over the fi rst year. Our MCS results call for additional multidisciplinary resources to support patients' psychologic health.…”

Section: Effect Of Sex Native Disease Age and Transplant Type On Tmentioning

confidence: 99%

Impact of Lung Transplantation on Recipient Quality of Life

Copeland

Vock

Pieper

et al. 2013

Chest

View full text Add to dashboard Cite

A dvanced lung disease severely impairs the quality of life (QOL) and survival of millions of individuals and lacks highly effective medical therapies. Lung transplantation has emerged as a viable treatment option for select patients with end-stage lung disease, providing 1-and 3-year survival rates of 79% and 64%, respectively. 1 In fact, lung transplantation represents the only commonly transplanted solid organ with a steady rise in international volume in recent years, with 3,272 patients undergoing lung transplantation in 2009. Although lung transplant appears to provide a short-term survival benefi t for most patients regardless

show abstract

“…Newer therapies, directed at reducing pulmonary vascular load, have been shown to improve symptoms, quality of life, functional capacity, and, in the case of IV epoprostenol, survival. [2][3][4][5][6][7][8][9][10][11] However, PAH remains a disease without a cure in the absence of lung transplantation.…”

mentioning

confidence: 99%

Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension

Mathai

Hassoun

Puhan

et al. 2015

Chest

View full text Add to dashboard Cite

BACKGROUND: Pulmonary arterial hypertension (PAH) is a progressive disease with high rates of morbidity and mortality. Current therapies improve symptoms, functional capacity, and, in select cases, survival. Little is known about patient factors that may predict the likelihood of patient-important, clinically relevant responses to therapy such as the 6-min walk distance (6MWD) and health-related quality of life (HRQoL).

show abstract

Sildenafil Improves Health-Related Quality of Life in Patients With Pulmonary Arterial Hypertension*

Cited by 87 publications

References 21 publications

Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension

Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension

Impact of Lung Transplantation on Recipient Quality of Life

Sex Differences in Response to Tadalafil in Pulmonary Arterial Hypertension

Contact Info

Product

Resources

About